

## Congratulations to *TLCR*'s Honorary Editor-in-Chief, Editorial Board Member and Author for winning three IASLC distinguished awards

Melanie C. He

Editorial Office, Translational Lung Cancer Research, AME Publishing Company, Guangzhou 510000, China

Correspondence to: Melanie C. He, Science Editor. Editorial Office, Translational Lung Cancer Research, AME Publishing Company, Room 11, 14/F, Chuangzhan Harbor Building, No. 82, Jiangnan Main Road, Haizhu District, Guangzhou 510000, China. Email: editor@tlcr.org.

Submitted Oct 02, 2015. Accepted for publication Oct 12, 2015.

doi: 10.3978/j.issn.2218-6751.2015.10.06

View this article at: <http://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.06>

The 16<sup>th</sup> World Conference on Lung Cancer (WCLC) was held in Denver, USA from September 6 to September 9, 2015. At the opening ceremony of this grand conference on September 6, the International Association for the Study of Lung Cancer (IASLC) presented four IASLC distinguished awards to the scientists who have made outstanding scientific contributions and achievements in the field of lung cancer and other thoracic malignant research. The four distinguished awards were IASLC Paul A. Bunn, Jr. Scientific Award (Formerly IASLC Scientific Award), IASLC Merit Award, Joseph W. Cullen Prevention/Early Detection Award, and Mary J. Matthews Pathology/Translational Research Award.

The exciting news is that, the Honorary Editor-in-Chief, Editorial Board Member and Author of *Translational Lung*

*Cancer Research (TLCR)*, have respectively won three out of the four IASLC distinguished awards (*Figure 1*). The IASLC Paul A. Bunn, JR. Scientific Award was given to Professor Yi-Long Wu from China, the Honorary Editor-in-Chief of *TLCR*; the Mary J. Matthews Pathology/Translational Research Award given to Professor Ming Sound Tsao from Canada, the Editorial Board Member of *TLCR*; and the Joseph W. Cullen Prevention/Early Detection Award given to Professor Jacek Jassem, Author of *TLCR* and Editorial Board Member of *Annals of Translational Medicine (ATM)*.

### IASLC Paul A. Bunn, Jr. Scientific Award (Formerly IASLC Scientific Award)

The IASLC Scientific Award of WCLC 2015 was given to



**Figure 1** *TLCR*'s Honorary Editor-in-Chief, Editorial Board Member and Author have respectively won three out of the four IASLC distinguished awards. *TLCR*, *Translational Lung Cancer Research*; IASLC, International Association for the Study of Lung Cancer.



**Figure 2** Professor Yi-Long Wu, China.

Professor Yi-Long Wu (*Figure 2*), for his lifetime scientific contributions in thoracic malignancy research and his contribution to the organization's development.

Professor Yi-Long Wu is vice president of the Guangdong General Hospital & Guangdong Academy of Medical Sciences and director of Guangdong Lung Cancer Institute. He is the president of Chinese Society of Clinical Oncology (CSCO), the past director of Chinese Society of Lung Cancer (CSLC), the president of the Chinese Thoracic Oncology Group (C-TONG), the president of International Chinese Society of Thoracic Surgery (ICSTS), a fellow of the American College of Surgeons, a member of the Staging Committee and board of directors of the IASLC and a member of the International Affairs Committee of American Society of Clinical Oncology (ASCO).

He graduated from Sun Yat-sen University of Medical Sciences in 1982, and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer from basic science to bedside and evidence-based medicine in oncology. He is leading the Chinese lung cancer field and has been a principle investigator (PI) or Co-PI in more than 90 multi-center clinical trials. He has contributed 20 books on cancer and has published more than 300 articles in peer-reviewed journals including *J Clin Oncol*, *Lancet Oncol*, *New Engl J Med*, *Cancer Cell* and *J Thorac Oncol*. He also serves on the editorial boards of *Cancer Letters*, *Annals of Surgical Oncology*, *Lung Cancer Management*, *International Journal of Biological Marker* and



**Figure 3** Professor Ming Sound Tsao, Canada.

*General Thoracic and Cardiovascular Surgery*. He is Editor-in-Chief of *Journal of Evidence-Based Medicine*, *Journal of Thoracic Oncology (Chinese Edition)*, and *Oncologist (Chinese Edition)* etc.

Prof. Yi-Long Wu is also the Honorary Editor-in-Chief of *TLCR*. He has contributed multiple articles including “Clinical trials for lung cancer in China” and “Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer” to *TLCR*, and guest-edited the focused issue “Personalized Therapy in Lung Cancer”, which was published on *TLCR* in December 2014 (Vol 3, No 6): <http://www.tlcr.org/issue/view/123>.

### **Mary J. Matthews Pathology/Translational Research Award**

The Mary J. Matthews Award this year was given to Professor Ming Sound Tsao (*Figure 3*), who has made lifetime scientific achievements in pathology-translational research of thoracic malignancies.

Professor Ming Sound Tsao is a Thoracic Pathologist and Senior Scientist at the Princess Margaret Cancer Centre, Professor of Laboratory Medicine and Pathobiology, and the M. Qasim Choksi Chair in Lung Cancer Translational Research at the University of Toronto, Canada.

Professor Ming Sound Tsao received his B.Sc. from the Simon Fraser University and M.D. from the University of British Columbia. He trained as an anatomic pathologist at McGill University, and as an experimental pathologist at the



**Figure 4** Professor Jacek Jassem, Poland.

University of North Carolina School of Medicine at Chapel Hill. He was a past faculty member in the Department of Pathology at McGill University and the Montreal General Hospital, Montreal, Canada.

Professor Ming Sound Tsao is a member and past chair of the IASLC Pathology Committee, a member of the IASLC Staging and Prognostic Factor Committee, and a co-editor of the IASLC Atlas of ALK Testing in Lung Cancer. He was a past Associate Editor of the *Journal of Thoracic Oncology* and is an Editorial Board Member of the *Journal of Clinical Oncology*.

Professor Ming Sound Tsao is the Chair of the Correlative Science and Tumor Biology Committee of the NCIC Clinical Trials Group. He has published more than 390 peer-reviewed manuscripts. His clinical and translational research interests include prognostic and predictive factors, including gene expression signature and genomic pathology in non-small cell lung cancer, and standardization of molecular testing in lung cancer.

Professor Ming Sound Tsao received the 2011 O. Harold Warwick Award from the Canadian Cancer Society, given to a scientist whose research has had a major impact on cancer control in Canada.

As the Editorial Board Member of *TLCR*, Professor Ming Sound Tsao has contributed various articles on pathology for *TLCR*, such as “Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review” and “Prognostic markers in lung cancer: is it ready for prime time?”.

### Joseph W. Cullen Prevention/Early Detection Award

The Joseph W. Cullen Award this year was given to Professor Jacek Jassem (*Figure 4*), for his lifetime scientific achievements in prevention research of thoracic malignancies.

Jacek Jassem, MD, PhD, is a full Professor of Clinical Oncology and Radiotherapy and the head of the Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland. He received his MD degree, and his PhD degree from the Medical University of Gdańsk, Poland, and also trained in oncology at the Karolinska Institute in Stockholm and National Cancer Institute in Amsterdam.

His main scientific interests are lung cancer, breast cancer and molecular oncology. He has (co)authored over 500 full articles, patents, books and book chapters in this field. He has been actively involved in different editorial boards including *Lancet Oncology*, *European Journal of Cancer*, *Cancer Treatment Reviews*, *Radiotherapy and Oncology* and *Journal of Thoracic Oncology*. The cumulated impact factor of his full publications is over 1,680, with over 14,200 citations and h-index of 46.

He is the recipient of several Polish and international scientific awards. He is the past-chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group and the EORTC Executive Committee, the chairman of the Central and East European Oncology Group, the past chairman of the ASCO International Affairs Committee, and the immediate past-president of the Polish Oncological Society.

He is a member of the European Academy of Cancer Sciences and Polish Academy of Art and Sciences. His is currently a European Society for Medical Oncology (ESMO) Executive Board member. Professor Jassem has contributed to several radio and TV programs and articles in lay press on the role of science in the development of public health and oncology, and is an author of “Polish anti-tobacco legislation” (introduced by the Parliament in 2010).

He also undertook nationwide public health initiatives, such as and the coordination of Cancer Control Strategy for Poland 2015-2024. Professor Jassem is a member of the IASLC Smoking Cessation and Tobacco Control Committee.

Professor Jassem has also contributed the great article “Tobacco control in Poland—successes and challenges” in *TLCR*'s special issue dedicated to the 14<sup>th</sup> Central European Lung Cancer Conference (CELCC). Professor Jassem is also the editorial board member of our sister journal *ATM*,

and the special interview of Professor Jassem is published on *ATM*, Vol 3, No 2 (February 2015)—Prof. Jacek Jassem: we should be more aggressive about tobacco control in fighting against lung cancer.

Congratulations on the three eminent scientists who have contributed to *TLCR*, not only for their awards obtained, but also for all the significant contributions and achievements they have made for the progresses in the medical field. Moreover, we would specially like to express our utmost appreciation to the three prominent scientists for their lasting contributions and support to our journal *TLCR*! We will continue to provide a creative and

enthusiastic arena to work with all the distinguished experts worldwide toward the next breakthrough in the field of lung cancer and thoracic diseases.

### **Acknowledgements**

None.

### **Footnote**

*Conflicts of Interest:* The author has no conflicts of interest to declare.

**Cite this article as:** He MC. Congratulations to *TLCR*'s Honorary Editor-in-Chief, Editorial Board Member and Author for winning three IASLC distinguished awards. *Transl Lung Cancer Res* 2015;4(5):668-671. doi: 10.3978/j.issn.2218-6751.2015.10.06